Ekomed Agrees to Collaboration on TB Immunotherapy
03 Março 2011 - 12:07PM
Immune Network Ltd. (Pink Sheets:IMMFF) advises that Ukrainian
company Ekomed LLC has agreed to collaborate with Immune Network
and Immunitor for further clinical research of a tableted form of
Ekomed's well-known immunomodulator herbal product
Immunoxel/Dzherelo.
The new tableted Ekomed product has been the subject of a series
of small clinical trials in eastern Ukraine, which demonstrated
improved efficacy and shortened duration of treatment compared to
the liquid tincture form. Ekomed is presenting these latest
clinical results this week at the 18th Union TB and Lung Diseases
Conference of the African Region in Nigeria.
Immunoxel/Dzherelo has been demonstrated in a dozen published
clinical trials to have a powerful effect against active
tuberculosis, including the severe drug-resistant forms (MDR-TB and
XDR-TB) and a significant improvement in HIV-patients vs
standard therapy. For example, in dually TB/HIV co-infected
patients Immunoxel/Dzherelo statistically significantly increased
the absolute number of CD4 T-cells by 71%, the CD4/CD8
cell ratio by 25%, and the number of total CD3+ lymphocytes by 27%.
The standard therapy resulted in deterioration of all these
characteristics. The viral load decreased by 70% in the
Immunoxel/Dzherelo group but increased in the cohort on standard
therapy. In HIV-patients Immunoxel/Dzherelo
statistically significantly (1.8 times) increased the number of CD4
cells vs standard therapy, reduced hepatic toxicity (by 50%
reduction of the initial/baseline values of ALT
aminotransferase) vs increase in hepatic toxicity in patients on
standard therapy. Immunoxel/Dzherelo was safe, contrasted with
numerous side effects in the group on standard therapy.
Immunoxel/Dzherelo increased body weight of patients by 5.7 kg vs
1.4 kg effect of standard therapy.
The new tableted formulation has major advantages in lower cost
of production and of distribution, and is expected to exhibit much
greater patient compliance.
Although Immunoxel/Dzherelo is classified as an immunomodulator,
similar in some pharmacological respects to Immunitor's V5, there
are clinical and basic scientific differences between the
products. The focus of Immune Network's future clinical trials
will be to optimize the use of the products alone and in
combination. Clinical trials will initially be conducted in
one or more African countries and in Ukraine, with a focus on
patients who suffer from MDR-TB or TB with HIV co-infection
(TB/HIV).
The market potential for products such as Immunitor's V5 and
Ekomed's Immunoxel/Dzherelo is large, since there are 9 million new
cases of TB annually and 2 billion people are infected with the
bacillus. Severe forms of TB – MDR-TB, XDR-TB and TB/HIV – are
global health priorities. Immune Network, Immunitor, and
Ekomed are committed to the principles of availability and
affordability for the patients who need such products the
most.
Under the agreed-upon principles of its collaboration with
Ekomed, Immune Network will contribute to the costs and assist in
the conduct of the proposed clinical trials. The parties will
establish a framework for profit sharing relevant to the possible
combined global marketing and clinical use of the products.
For additional information about Immunitor company, please visit
http://www.immunitor.com. For Ekomed, please visit
http://www.ekomed.com.ua.
The website for Immune Network is at
http://www.immune-network.com.
The Immune Network Ltd. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008.
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd.
IMMFF@yahoo.com
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Omni Bridgeway (PK) (USOTC:IMMFF)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024